昭衍新藥(603127.SH):擬認購廈門源峯基金2億元的基金份額
格隆匯3月30日丨昭衍新藥(603127.SH)公佈,為了藉助專業投資機構在投資研發能力及項目資源上的獨特優勢,夯實產業基礎並佈局產業前沿領域,北京昭衍新藥研究中心股份有限公司與廈門源峯投資有限公司(簡稱“廈門源峯投資”)於2022年3月30日簽署《廈門源峯股權投資基金合夥企業(有限合夥)有限合夥協議》,公司擬認購廈門源峯股權投資基金合夥企業(有限合夥)(簡稱“廈門源峯基金”)人民幣2億元的基金份額,資金來源為自有資金。廈門源峯基金擬募資規模為人民幣200億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.